Faculdade de Farmácia, Universidade Federal de Minas Gerais, Avenida Antonio Carlos, 6627, CEP 31270-901, Belo Horizonte, Brazil, and College of Pharmacy, University of Hawaii at Hilo, Hilo, Hawaii ...

A ctDNA-guided approach can help identify when patients with HR-positive advanced breast cancer are developing an ESR1 ...

The angiotensin‐receptor neprilysin inhibitor (ARNI) sacubitril/valsartan was shown to be superior to the angiotensin‐converting enzyme inhibitor enalapril in terms of reducing cardiovascular ...

Objective To determine whether new users of proton pump inhibitors (PPIs) are at an increased risk of gastric cancer compared with new users of histamine-2 receptor antagonists (H2RAs). Design Using ...

Switching to camizestrant, a next-generation oral SERD, significantly prolongs progression-free survival and maintains ...

Kisqali plus aromatase inhibitor improved outcomes across age and menopausal status in early hormone receptor–positive, HER2-negative breast cancer.

Novartis announces phase III NATALEE trial of Kisqali reduces risk of recurrence in younger patients with early breast cancer: Basel Tuesday, June 3, 2025, 18:00 Hrs [IST] Novarti ...

Median PFS increased from 1.94 months with single-agent fulvestrant to 5.32 months with the addition of ipatasertib. Patients ...

Medicinal Chemistry, Department of Pharmacy & Pharmacology and Sterix Limited, University of Bath, Claverton Down, Bath, BA2 7AY, U.K., Endocrinology & Metabolic Medicine and Sterix Limited, Faculty ...

Positive results from the SERENA-6 Phase III trial have shown that AstraZeneca’s camizestrant alongside a cyclin-dependent kinase (CDK) 4/6 inhibitor (palbociclib, ribociclib or abemaciclib) led to a ...

AstraZeneca has presented results for the SERENA-6 trial at the American Society for Medical Oncology (ASMO)'s 2025 ...